2026-04-17T14:16:42Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/87892025-10-24T10:23:47Zcom_2072_378070com_2072_378040col_2072_378092

Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE‐SPECT ESUS Trial Del Brutto, Victor Diener, Hans Christoph Easton, J. Donald Granger, Christopher Cronin, Lisa Kleine, Eva Molina Cateriano, Carlos Malalties cerebrovasculars - Factors de risc Embòlia - Factors de risc DISEASES::Cardiovascular Diseases::Vascular Diseases::Embolism and Thrombosis::Embolism DISEASES::Cardiovascular Diseases::Vascular Diseases::Cerebrovascular Disorders::Stroke ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors ENFERMEDADES::enfermedades cardiovasculares::enfermedades vasculares::embolia y trombosis::embolia ENFERMEDADES::enfermedades cardiovasculares::enfermedades vasculares::trastornos cerebrovasculares::accidente cerebrovascular TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo Risk factors; Secondary prevention; Stroke predictors Factores de riesgo; Prevención secundaria; Predictores de accidentes cerebrovasculares Factors de risc; Prevenció secundària; Predictors d'accidents cerebrovasculars Background We sought to determine recurrent stroke predictors among patients with embolic strokes of undetermined source (ESUS). Methods and Results We applied Cox proportional hazards models to identify clinical features associated with recurrent stroke among participants enrolled in RE‐SPECT ESUS (Randomized, Double‐Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic Stroke of Undetermined Source) trial, an international clinical trial evaluating dabigatran versus aspirin for patients with ESUS. During a median follow‐up of 19 months, 384 of 5390 participants had recurrent stroke (annual rate, 4.5%). Multivariable models revealed that stroke or transient ischemic attack before the index event (hazard ratio [HR], 2.27 [95% CI, 1.83–2.82]), creatinine clearance <50 mL/min (HR, 1.69 [95% CI, 1.23–2.32]), male sex (HR, 1.60 [95% CI, 1.27–2.02]), and CHA2DS2‐VASc ≥4 (HR, 1.55 [95% CI, 1.15–2.08] and HR, 1.66 [95% CI, 1.21–2.26] for scores of 4 and ≥5, respectively) versus CHA2DS2‐VASc of 2 to 3, were independent predictors for recurrent stroke. Conclusions In RE‐SPECT ESUS trial, expected risk factors previously linked to other common stroke causes were associated with stroke recurrence. These data help define high‐risk groups for subsequent stroke that may be useful for clinicians and for researchers designing trials among patients with ESUS. This study was supported by Boehringer Ingelheim. 2025-10-24T10:23:47Z 2025-10-24T10:23:47Z 2025-10-24T10:23:47Z 2023-01-10T08:05:50Z 2023-01-10T08:05:50Z 2022-06-07 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/8789 Journal of the American Heart Association;11(11) https://doi.org/10.1161/JAHA.121.023545 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Wiley Scientia